Safety and tolerability evaluation showed that all patients experienced at least one treatment-emergent adverse event during the course of the study, including neutropenia (95%), leukopenia (85%), thrombocytopenia (65%), lymphopenia (55%), hypoalbuminemia (50%), aspartate aminotransferase elevation (35%), glutamyl transpeptidase elevation (30%), anemia (25%), and alanine aminotransferase elevation (25%). The gene discussed is GPT; the disease is Decreased total neutrophil count.